Spectrum of Activity


General Information

C. difficile Infection (CDI)


  • A second or subsequent recurrence following treatment with oral vancomycin; or
  • Treatment failure with oral vancomycin for the current CDI episode; or
  • An intolerance or contraindication to oral vancomycin.
  • Re-treatment with fidaxomicin will only be considered for a relapse occurring within 8 weeks of the completion of the most recent fidaxomicin course. CDI occurring beyond 8 weeks after the completion of the most recent fidaxomicin course will require a trial with vancomycin, unless there is a documented allergy, severe adverse reaction or intolerance to prior oral vancomycin use.

Criteria for use: Vancomycin treatment failure defined as 14 days of vancomycin therapy without acceptable clinical improvement and without other identified cause of persistent darrhea


  • Do not use for systemic infections (absorption is negligible)

Use with caution in patients with a history of macrolide allergy, risk of hypersensitivity cross reaction

- GI disturbance - Cytopenias - Hypersensitivity: facial, tongue or throat swelling

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None